Cipla (CIPLA) Q4 19/20 earnings summary

Executive summary

• FY20 delivered 5% revenue growth, stable EBITDA margin near 19%, and record PAT attributable to owners of ₹1,547 crore despite Goa remediation and emerging-market supply challenges.

• COVID-19 response prioritized uninterrupted medicine supply; partnerships supported remdesivir, tocilizumab and favipiravir access, alongside community relief initiatives.

Financial highlights

• Consolidated revenue rose 5% YoY to ₹17,132 crore; five-year revenue CAGR was 9%.

• EBITDA was ₹3,230 crore, with margin near 19%; PAT attributable to owners reached a record ₹1,547 crore, or 9% of sales.

• Consolidated EPS was ₹19.16 versus ₹18.93 in FY19; effective tax rate was 29%.

• Cash flow from operations rose to ₹3,068 crore from ₹1,691 crore; free cash flow increased to ₹1,955 crore from ₹1,043 crore.

Outlook and guidance

• FY21 priorities: business reimagination, cost optimization, cash management, prudent inventory and reliable supply of critical materials and finished goods.

• India plans market-beating growth through One India; US focus is maximizing value from key assets, including Albuterol, and monitoring respiratory filings.

• South Africa aims to sustain private-market momentum and OTC leadership; Europe and emerging markets will prioritize selected DTM markets and long-term-value products.

• R&D investment is expected to moderate in FY21 after generic Advair trials and filing; spending will focus on select value-accretive opportunities.